ARTICLE | Clinical News
Ganaxolone: Phase II started
February 23, 2015 8:00 AM UTC
Marinus began an open-label, U.S. Phase II trial to evaluate daily ganaxolone given as either oral liquid suspension or capsules for up to 26 weeks in about 10 girls ages 2-10 with confirmed mutations...